PMV Pharma Appoints CMO

PMV Pharmaceuticals announced the appointment of Dr. Salim Yazji as chief medical officer.  Dr. Yazji was most recently executive vice president and chief medical officer at Calimmune, Inc.

“Salim’s depth of experience and proven leadership in shepherding innovative products from pre-clinical development through product approval will be critical as we advance towards the clinic,” said David Mack, Ph.D., president and chief executive officer of PMV Pharma.  “We are delighted to welcome Salim to our team. Salim’s rich experience in leading oncology clinical trials and drug development will help define our clinical and regulatory strategies for our multiple programs.” Salim will be based in the Boston area where the Company’s clinical and regulatory operations will be located. 

“PMV Pharma is at the forefront of developing transformational products in oncology,” said Dr. Salim Yazji. “I am thrilled to join the PMV Pharma team at this important juncture with the opportunity to work alongside a highly skilled scientific team, key opinion leaders and management team.”

Dr. Yazji will apply over 20 years of experience to the leadership of PMV Pharma’s clinical development and regulatory teams. At Calimmune, he led the clinical and regulatory teams through the company’s sale to CSL Behring.